OXTHERA INTELLECTUAL PROPERTY AB

OXABACT

pharmaceutical product for the treatment of kidney stones;

OXABACT

Pharmaceutical product for the treatment and prevention of chronic kidney disease;

OXABACT

Pharmaceutical preparations for use in urology, gastroenterology, oncology and immunology and for the treatment of diabetes, infectious diseases, inflammation and metabolic diseases, all for therapeutic use; pharmaceutical preparations for the treatment of kidney stones; pharmaceutical products for the treatment and prevention of kidney diseases in patients with hyperoxaluria;

OXAZYME

pharmaceutical product containing a recombinant enzyme for the treatment of kidney stones;

OXAZYME

Pharmaceutical product for the treatment and prevention of kidney stones;

OXTHERA

Pharmaceutical preparations for treating kidney disease, nephrocalcinosis and kidney stones and hyperoxalemia and hyperoxaluria; urological pharmaceutical preparations;

OXTHERA

(Based on 44(e)) Pharmaceutical preparations and substances for use in nephrology, urology, kidney-related diseases and for the treatment of kidney stones and hyperoxaluria;Scientific and technological services, namely, research in the field of pharmaceutics, tissue engineering and regenerative medicine; scientific research services; medical and scientific research; pharmaceutical research and development; and clinical testing, namely, conducting clinical trials in the field of pharmaceutical preparations, drugs, cell therapy, gene therapy and cancer therapy; bioassays for industrial and scientific purposes; technology advisory and consultancy services relating to the provision of the aforesaid services, and providing information relating to the provision of the aforesaid services;

OXTHERA

Pharmaceutical preparations for use in urology, nephrology, gastroenterology, oncology and immunology and for the treatment of diabetes, infectious diseases, inflammation and metabolic diseases, all for therapeutic use; pharmaceutical preparations for the treatment of kidney stones; pharmaceutical products for the treatment and prevention of kidney diseases in patients with hyperoxaluria;Retail store services featuring goods in the fields of pharmaceuticals, medical preparations, vaccines, natural remedies, diagnostics and medical devices; goods import-export agencies; sales promotion for others in the fields of pharmaceuticals, medical preparations, vaccines, natural remedies, diagnostics and medical devices;Scientific and technological services, namely, research and design in the fields of pharmaceutics, tissue engineering and regenerative medicine; analysis of industrial fluids and scientific research services; medical, biological, chemical and scientific research; industrial research in the fields of pharmaceutics, tissue engineering and regenerative medicine; pharmaceutical research and development; research and development of new products in the nature of new medicines and medical preparations; medical and chemical laboratories; clinical testing, namely, conducting clinical trials for others in the fields of pharmaceutical preparations, drugs, cell therapy, gene therapy and cancer therapy; development of new products in the nature of probes, reagents and bioassays for industrial and scientific purposes; advisory, consultancy and information services relating to the provision of the aforesaid mentioned services, namely, advisory and consultancy services relating to medical, biological, chemical and scientific research, industrial research in the fields of pharmaceutics, tissue engineering and regenerative medicine, pharmaceutical research and development and conducting clinical trials and providing information in the fields of medical research, biological research, chemical research, scientific research and industrial research in the fields of pharmaceutics, tissue engineering and regenerative medicine;